Fidelity
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator noretreat, TOB, Seel
Search This Board:
Last Post: 4/17/2014 9:40:18 PM - Followers: 104 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1101   Well...I did pick up some IDRA at 2.26 Seel 04/17/14 09:40:18 PM
#1100   IDRA Daily Chart TOB 04/17/14 06:12:21 PM
#1099   Good/great call for sure.......... etradeedge 04/16/14 10:29:24 PM
#1098   Yup 3.01 Would like to see us open there binks 04/16/14 07:39:00 PM
#1097   We are bumping against the 200 day MA lookingforprofit 04/16/14 03:51:21 PM
#1096   Looking awesome now binks 04/16/14 03:15:00 PM
#1095   Golly, all we need is 2 or 3 tprosuper 04/16/14 03:14:09 PM
#1094   couldn't find enough angst to compel a sell... macnqueso 04/16/14 08:24:00 AM
#1093   Mop done. Shorts need to cover. Upturn begins tomorrow. Randolph Duke 04/15/14 09:19:39 PM
#1092   I got in today at 2.50 with 3k shares binks 04/15/14 06:00:03 PM
#1091   looks like they blew it out $2.29. nice Randolph Duke 04/15/14 03:43:23 PM
#1090   An exhaustion candle is when the price has lookingforprofit 04/15/14 03:21:44 PM
#1089   Whats that?? cdaniel394 04/15/14 02:56:20 PM
#1088   First post on this board. We may get lookingforprofit 04/15/14 02:55:34 PM
#1087   Where's the mop for this bloody mess? We Randolph Duke 04/15/14 12:43:02 PM
#1086   Possible bottom in IBB. Touch of 2.75 for Citrati 04/15/14 09:45:59 AM
#1085   No I think their first buy point was lucky9 04/14/14 02:39:03 PM
#1084   I would love a dip to $2.80. Hope Randolph Duke 04/14/14 09:50:58 AM
#1083   At this rate 2.80 looks real as this etradeedge 04/12/14 07:19:53 PM
#1082   trying to work up some angst to join macnqueso 04/10/14 05:48:24 PM
#1081   Is this Bio-tech gutting a BUY the Randolph Duke 04/10/14 05:40:54 PM
#1080   Market and IBB unleashing a flooding dump...Trying to Citrati 04/10/14 11:13:57 AM
#1079   The dragonfly doji was exactly was I was Anakiin 04/10/14 08:35:19 AM
#1078   E...the thing that makes me nervous about a Citrati 04/09/14 11:26:01 PM
#1077   Little help and B Bros woes continue..........short term etradeedge 04/09/14 11:09:11 PM
#1076   http://seekingalpha.com/news/1663963-idera-plus-5-percent-ah-on-positive-imominu Citrati 04/07/14 08:24:08 PM
#1075   Yup- more good news. If it wasn't for Randolph Duke 04/07/14 07:15:14 PM
#1074   http://www.4-traders.com/IDERA-PHARMACEUTICALS-INC-428572/news/Idera-Pharmaceuti Rhodey Red 04/07/14 04:28:15 PM
#1073   I'm watching closely, but will wait for the noretreat 04/06/14 08:17:19 PM
#1072   That is a calculation based on the IBB Canoepaddler 04/05/14 11:37:59 PM
#1071   50% off the highs, and moving into crash etradeedge 04/05/14 06:57:31 PM
#1070   They might need to prove out potential efficacy Seel 04/04/14 08:19:41 PM
#1069   Partnership announcement is what I'm looking for short Canoepaddler 04/04/14 07:51:58 PM
#1068   Partnership Canoepaddler 04/04/14 07:50:24 PM
#1067   I've never seen IND as big deal and Seel 04/04/14 06:55:02 PM
#1066   noretreat....good points. I am not paying much attention Citrati 04/04/14 06:45:30 PM
#1065   Almost across the board in biotech, IND's that noretreat 04/04/14 06:22:44 PM
#1064   True - it doesn't look like IDRA will Seel 04/04/14 05:32:36 PM
#1063   Idra has dropped over 40%...so I would say noretreat 04/04/14 04:56:20 PM
#1062   If you like chart plays, then take a Citrati 04/04/14 02:30:24 PM
#1061   NR....3.50 could hold. The real issue is whether Citrati 04/04/14 02:25:03 PM
#1060   I'm calling it. Right here. THEPK5 04/04/14 12:33:05 PM
#1059   Anyone see the bottom here? noretreat 04/04/14 12:00:02 PM
#1058   The major issue right now is the sector Citrati 04/04/14 11:50:13 AM
#1057   Thoughts now? Support? THEPK5 04/04/14 11:38:02 AM
#1056   IDRA Presentation at AACR : April 7th 1PM-5PM Ned Serious 04/03/14 10:41:09 PM
#1055   IDRA has been suffering from the sector weakness. TOB 04/03/14 09:31:09 PM
#1054   This stock is killing me as of late. tprosuper 04/03/14 09:21:20 PM
#1053   Not a purchase... but at least the Directors CHM_760 04/03/14 06:38:06 PM
#1052   Good to see a couple of directors purchase cdaniel394 04/03/14 06:13:22 PM
PostSubject